Base Working Capital. Base Working Capital is US$575 million to US$700 million and references in this Agreement to amounts being in excess of, greater than or less than Base Working Capital shall mean less than US$575 million and greater than or in excess of US$700 million.
Appears in 2 contracts
Sources: Share and Business Sale Agreement (Glaxosmithkline PLC), Share and Business Sale Agreement (Glaxosmithkline PLC)